Verona Pharma plc (VRNA)
| Market Cap | 9.56B |
| Revenue (ttm) | 118.54M |
| Net Income (ttm) | -163.94M |
| Shares Out | 91.14M |
| EPS (ttm) | -2.02 |
| PE Ratio | n/a |
| Forward PE | 87.81 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 15,988,724 |
| Open | 104.78 |
| Previous Close | 104.77 |
| Day's Range | 104.76 - 104.99 |
| 52-Week Range | 16.91 - 104.99 |
| Beta | 0.24 |
| Analysts | Buy |
| Price Target | 112.40 (+7.2%) |
| Earnings Date | Aug 7, 2025 |
About VRNA
Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company offers Ohtuvayre, a dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that combines bronchodilator and non-steroidal anti-inflammatory effects for the maintenance treatment of chronic obstructive pulmonary disease, as well as cystic fibrosis and asthma. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom. [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for VRNA stock is "Buy." The 12-month stock price target is $112.4, which is an increase of 7.20% from the latest price.
News
Major deals involving U.S. drugmakers and biotechs over the past decade
Merck is acquiring UK-based Verona Pharma for about $10 billion, as part of the U.S. drugmaker's strategy to diversify beyond its blockbuster cancer treatment Keytruda.
Merck to Buy Verona Pharma for Around $10 Billion
Merck agreed to buy respiratory drugmaker Verona Pharma for about $10 billion as it tries to make up for huge expected patent losses. Sales could fall by $18 billion over the next five years.
Two big reasons why buying Verona was crucial for Merck
Verona Pharma Plc (NASDAQ: VRNA) rallied about 20% on Wednesday after Merck & Co Inc (NYSE: MRK) said it will buy the UK-based biotech firm known for its COPD drug Ohtuvayre. The $10 billion all-cash ...
Merck has struck a roughly $10 billion deal to buy Verona Pharma
The move bolsters Merck's lineup as it braces for the 2028 loss of patent exclusivity for blockbuster cancer drug Keytruda.
Verona Pharma shares jump with Merck set to acquire company in $10 billion deal
Merck announced Wednesday it will acquire UK-based Verona Pharma for approximately $10 billion, deepening its commitment to respiratory treatments as the company prepares for a revenue gap following t...
Merck dives into COPD treatments with $10 billion purchase of Verona Pharma
Verona Pharma's stock soars toward a record after $10 billion buyout deal with Merck.
Verona Pharma Stock Jumps 21%. It's Being Bought for $10 Billion by Merck.
The deal is expected to close in the fourth quarter of 2025.
Merck to Buy Verona Pharma in $10 Billion Deal
Merck has struck a roughly $10 billion deal to buy Verona Pharma, bolstering its lineup as it braces for the 2028 loss of patent exclusivity for the blockbuster cancer drug Keytruda.
Merck to acquire Verona Pharma for $10 billion
Merck will buy UK-based Verona Pharma for about $10 billion, the companies said on Wednesday, strengthening the U.S. firm's presence in respiratory treatments as it readies for the patent expiry of it...
Merck to Acquire Verona Pharma, Expanding its Portfolio to Include Ohtuvayre® (ensifentrine), a First-In-Class COPD Maintenance Treatment for Adults and Expected to Drive Growth into the Next Decade
RAHWAY, N.J. & RALEIGH, N.C.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical comp...
Merck nears $10 billion deal for respiratory drugmaker Verona, FT reports
Merck is nearing a roughly $10 billion deal to buy lung disease-focused biotech Verona Pharma, the Financial Times reported on Wednesday.
Verona Pharma: A Blockbuster Franchise In The Making
Ohtuvayre's rapid US launch has driven explosive revenue growth, with Q1 2025 sales up 95% sequentially and refill rates signaling strong patient demand. With blockbuster potential, Wall Street projec...
Mizuho's Jared Holz details potential biotech, pharma acquisitions
Mizuho's Jared Holz joins the 'Fast Money' team to discuss the potential impact of expiring patents within the biotech and pharmaceuticals industries.
Verona Pharma Announces June 2025 Investor Conference Participation
LONDON and RALEIGH, N.C., May 21, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will participate in fireside chats at th...
Verona Pharma to Present Seven Analyses of the Phase 3 ENHANCE Studies in COPD at ATS 2025
Analyses support Ohtuvayre® (ensifentrine) as a first-in-class selective dualinhibitor of PDE3 and PDE4 for a broad COPD population
Silencing The Doubters: Verona Pharma Could Be Sitting On A Blockbuster
VRNA's COPD drug Ohtuvayre shows impressive Q1'25 net sales of $71.3M in just its third quarter of sales, all but confirming the blockbuster future of the drug. Ongoing R&D and trials, including a pha...
Verona Pharma plc (VRNA) Q1 2025 Earnings Call Transcript
Verona Pharma plc (NASDAQ:VRNA) Q1 2025 Earnings Conference Call April 29, 2025 9:00 AM ET Company Participants Victoria Stewart - Senior Director, Investor Relations and Communications David Zaccard...
Verona Pharma Reports First Quarter 2025 Financial Results and Provides Corporate Update
Total net revenue of $76.3 million from Q1 2025 driven by Ohtuvayre ® net sales of $71.3 million (+95% vs Q4 2024)
Verona Pharma's Bull Case Holds, But Lifecycle Extension Is Critical
Ohtuvayre's robust launch for COPD treatment exceeded expectations, with Q4 revenue of $36.6 million and FY24 revenue of $42.3 million, indicating strong market demand. Verona's financial health is so...
Verona Pharma Announces Amended Strategic Financing with Oaktree and OMERS
RIPSA interests repurchased Term loan facility increased to $450 million with more favorable terms Access to up to an additional $200 million LONDON and RALEIGH, N.C., March 28, 2025 (GLOBE NEWSWIRE) ...
Verona Pharma plc (VRNA) Q4 2024 Earnings Call Transcript
Verona Pharma plc (NASDAQ:VRNA) Q4 2024 Earnings Conference Call February 27, 2024 9:00 AM ET Company Participants David Zaccardelli - President and CEO Mark Hahn - CFO Christopher Martin - CCO Confe...
Verona Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Ohtuvayre TM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024
Verona Pharma Announces March 2025 Investor Conference Participation
LONDON and RALEIGH, N.C., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the ...
Verona Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update
LONDON and RALEIGH, N.C., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the fourth quart...
Verona Pharma's Ohtuvayre Defies Expectations In Q4, But Stock Alpha May Now Be Limited
Verona Pharma's Ohtuvayre, a novel COPD treatment, achieved $36 million in Q4 sales, indicating strong market interest and unmet need for new therapies. Despite aggressive pricing, Ohtuvayre's broad l...